Vaccination strategies against Zika virus.
Curr Opin Virol
; 23: 59-67, 2017 04.
Article
en En
| MEDLINE
| ID: mdl-28432975
ABSTRACT
The epidemic emergence of Zika virus (ZIKV) in 2015-2016 has been associated with congenital malformations and neurological sequela. Current efforts to develop a ZIKV vaccine build on technologies that successfully reduced infection or disease burden against closely related flaviviruses or other RNA viruses. Subunit-based (DNA plasmid and modified mRNA), viral vectored (adeno- and measles viruses) and inactivated viral vaccines are already advancing to clinical trials in humans after successful mouse and non-human primate studies. Among the greatest challenges for the rapid implementation of immunogenic and protective ZIKV vaccines will be addressing the potential for exacerbating Dengue virus infection or causing Guillain-Barré syndrome through production of cross-reactive immunity targeting related viral or host proteins. Here, we review vaccine strategies under development for ZIKV and the issues surrounding their usage.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
3_ND
Problema de salud:
2_enfermedades_transmissibles
/
3_dengue
/
3_neglected_diseases
Asunto principal:
Vacunas Virales
/
Vacunas de ADN
/
Virus Zika
/
Infección por el Virus Zika
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Virol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos